Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences
Six poster presentations will take place at the upcoming conferences, including the Ninth International Congress of the Growth Hormone Research (GRS) and Insulin-like Growth Factors (IGF) Societies from
“These presentations highlight our ability to design product candidates that address unmet medical needs, using our innovative TransCon technology platform,” said
Details about the presentations are listed below. Following the sessions, the presentations will be available on the company’s website under Selected Publications in the Pipeline section.
GRS & IGF Societies (Seattle): TransCon Growth Hormone |
|
Title | Date/Time |
Meeting Unmet Needs: The Sustained-Release of Protein and Peptide Drugs Poster #15G (Late-breaking Abstract #231) |
Saturday, September 15 11:30 a.m. – 1:30 p.m. (Local time) |
Baseline Demographics of the TransCon Growth Hormone Phase 3 heiGHt Trial Poster #18 (Abstract #64) |
Sunday, September 16 11:30 a.m. – 1:30 p.m. (Local time) |
Boulder Peptide Symposium (Denver): TransCon Technology |
|
Title | Date/Time |
TransCon Technology for Sustained Delivery of Proteins, Peptides, and Small Molecules Oral presentation |
Wednesday, September 26 9:00 – 9:40 a.m. (Local time) |
ESPE (Athens, Greece): TransCon Growth Hormone |
|
Title | Date/Time |
The Rationale and Design of TransCon GH P2-P218 (Poster) |
Friday, September 28 1:15 – 2:15 p.m. (Local time) |
Baseline Demographics of the TransCon Growth Hormone Phase 3 heiGHt Trial P2-P219 (Poster) |
Friday, September 28 1:15 – 2:15 p.m. (Local time) |
ASBMR (Montreal): TransCon PTH |
|
Title | Date/Time |
The Effect of TransCon PTH on Bone Turnover in a Phase 1 Trial SUN-0027 (Poster) |
Friday, September 30 12:30 – 2:30 p.m. (Local time) |
The Design and Results of a Phase 1 TransCon PTH Trial in Healthy Volunteers MON-0045 (Poster) |
Monday, October 1 12:00 – 2:00 p.m. (Local time) |
About
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technology to create new and potentially best-in-class therapies.
Ascendis is headquartered in
For more information, please visit www.ascendispharma.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create potentially best-in-class therapies and (iii) our product pipeline. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (
Ascendis,
Internal contact: Scott T. Smith Chief Financial Officer (650) 352-8389 ir@ascendispharma.com Media contact:Ami Knoefler Head ofGlobal Communications (650) 739-9952 ack@ascendispharma.com Investor contact:Patti Bank Westwicke Partners (415) 513-1284 patti.bank@westwicke.com